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Alterations in erythrocyte fatty
acid composition in preclinical
Alzheimer’s disease
Kathryn Goozee1,2,3,4,5,6,7, Pratishtha Chatterjee3,4,5, Ian James8, Kaikai Shen3,6,9, Hamid
R. Sohrabi 2,3,4,6,7, Prita R. Asih5,10, Preeti Dave1, Bethany Ball5, Candice ManYan1, Kevin
Taddei3,6,7, Roger Chung4, Manohar L. Garg11 & Ralph N. Martins2,3,4,5,6,7
Brain and blood fatty acids (FA) are altered in Alzheimer’s disease and cognitively impaired individuals,
however, FA alterations in the preclinical phase, prior to cognitive impairment have not been
investigated previously. The current study therefore evaluated erythrocyte FA in cognitively normal
elderly participants aged 65–90 years via trans-methylation followed by gas chromatography.
The neocortical beta-amyloid load (NAL) measured via positron emission tomography (PET) using
ligand 18F-Florbetaben, was employed to categorise participants as low NAL (standard uptake value
ratio; SUVR < 1.35, N = 65) and high NAL or preclinical AD (SUVR ≥ 1.35, N = 35) wherein, linear
models were employed to compare FA compositions between the two groups. Increased arachidonic
acid (AA, p < 0.05) and decreased docosapentaenoic acid (DPA, p < 0.05) were observed in high
NAL. To differentiate low from high NAL, the area under the curve (AUC) generated from a ‘base
model’ comprising age, gender, APOEε4 and education (AUC = 0.794) was outperformed by base
model + AA:DPA (AUC = 0.836). Our findings suggest that specific alterations in erythrocyte FA
composition occur very early in the disease pathogenic trajectory, prior to cognitive impairment.
As erythrocyte FA levels are reflective of tissue FA, these alterations may provide insight into the
pathogenic mechanism(s) of the disease and may highlight potential early diagnostic markers and
therapeutic targets.
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the most common form of dementia.
While it is estimated that 47 million people worldwide are presently living with dementia, it has been projected to escalate to 76 million by 2030. Currently there is no definitive diagnosis or effective treatment for AD.
Understanding the molecular changes occurring from the preclinical stage of the disease, may present a better
chance to ameliorate AD related pathogenic changes prior to them becoming irreversible.
Given that fatty acids are essential components of cell membranes, playing a vital role in normal cellular functioning, several studies have reported altered brain fatty acid composition in AD1–3. Substantial evidence also
presents an association between altered blood fatty acid concentrations and, cognitive impairment and dementia
risk, particularly to that of AD4–6. Further, an increasing number of studies suggest that omega-3 (n-3) polyunsaturated fatty acids (PUFA), primarily docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are protective against cognitive impairment and dementia7–11, whereas arachidonic acid (AA), an omega-6 (n-6) PUFA,
contributes towards AD pathogenesis12–15.
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Low NAL

High NAL

p

Gender (M/F)

19/46

13/22

0.419

Age (years,
mean ± SD)

77.61 ± 5.55

79.22 ± 5.38

0.165

BMI
(mean ± SD)

27.38 ± 4.47

28.05 ± 4.73

0.486

Education
(years,
mean ± SD)

14.86 ± 3.31

13.66 ± 2.84

0.078

Total cholesterol
(mmol/L,
mean ± SD)

4.82 ± 0.98

4.35 ± 1.19

0.045

Triglycerides
(mmol/L,
mean ± SD)

1.34 ± 0.70

1.10 ± 0.42

0.071

HDL cholesterol
(mmol/L,
mean ± SD)

1.64 ± 0.55

1.52 ± 0.48

0.292

LDL cholesterol
(mmol/L,
mean ± SD)

2.39 ± 0.85

2.34 ± 0.88

0.794

Testosterone
(nmol/L,
mean ± SD),
males

14.43 ± 6.16

11.66 ± 3.77

0.160

Testosterone
(nmol/L,
mean ± SD),
females

1.45 ± 2.55

1.26 ± 0.81

0.738

Oestradiol
(pmol/L,
mean ± SD),
males

113.16 ± 47.83

117.23 ± 35.17

0.795

Oestradiol
(pmol/L,
mean ± SD),
females

91.22 ± 118.71

73.90 ± 28.97

0.523

APOE ε4
carriers (%)

7.69

45.71

0.00000848

MMSE
(mean ± SD)

28.50 ± 1.16

28.80 ± 1.10

0.225

FBB-PET SUVR
(mean ± SD)

1.15 ± 0.08

1.71 ± 0.26

—

HV% (left;
right lobes,
mean ± SD)

0.195 ± 0.020;
0.199 ± 0.021

0.194 ± 0.019;
0.199 ± 0.018

0.805; 0.890

Table 1. Characteristics of study participants. Baseline characteristics including gender, age, body mass index
(BMI), education, serum cholesterol, hormone levels, APOE ε4 status, mini mental state examination (MMSE)
scores, neocortical amyloid load (NAL) represented by the standard uptake value ratio (SUVR) of the ligand
18
F-Florbetaben (FBB) in the neocortical region normalised with that in the cerebellum and hippocampal
volume (HV) normalised by the intracranial volume, have been compared between study participants with
low NAL (SUVR < 1.35) and high NAL (SUVR ≥ 1.35). Chi-square test or linear models were employed as
appropriate. HDL: high density lipoprotein, LDL: low density lipoprotein.

The protective and deleterious effects of fatty acids have been explored with respect to cognitive impairment
and clinical AD, however alterations in fatty acid profiles in individuals within the preclinical stage of AD, prior
to any apparent cognitive impairment, have not been investigated before.
Since aberrant accumulation of neocortical beta-amyloid load (NAL) has been reported to begin 15–20 years
prior to the clinical manifestation of AD16, therefore serving as a preclinical feature of the disease, we compared
the erythrocyte fatty acid composition of cognitively normal participants with high NAL (Standard uptake value
ratio or SUVR ≥ 1.35) versus those with low NAL (SUVR < 1.35), to evaluate alterations in fatty acid metabolism
that manifest in the periphery, in the asymptomatic preclinical phase of AD, within this exploratory study.

Results

Cohort characteristics. Participant demographics, serum cholesterol and hormone levels, APOEε4 carrier

status, MMSE scores and neuroimaging data including NAL and hippocampal volume have been presented in
Table 1.
All participants had a MMSE score ≥26, indicating absence of cognitive impairment. While no significant differences in demographic data, hormone levels, MMSE and hippocampal volume were observed between low and
high NAL, the frequency of APOEε4 carriers was significantly higher in participants with high NAL compared to
those with low NAL (p < 0.0005).
Scientific Reports | 7: 676 | DOI:10.1038/s41598-017-00751-2
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Figure 1. Altered fatty acid levels in cognitively normal individuals with low and high NAL. Elevated
erythrocyte arachidonic acid levels and decreased docosapentaenoic acid (n-3) levels were observed in
individuals with high NAL (N = 35) compared to those with low NAL (N = 65), based on standard uptake
value ratio cut off score of 1.35. Fatty acid concentrations were measured in arbitrary units (AU). ‘*’ represents
p < 0.05, adjusted for covariates age, gender, years of education and APOE ε4 status; NAL: neocortical amyloid
load measured via positron emission tomography, using ligand 18F-Florbetaben. The error bars represent SE.

Erythrocyte fatty acids and demographic characteristics. Among the erythrocyte FA measured, lin-

oleic acid (C18:2n-6, β = −0.228, p = 0.022) and DHA (C22:6n-3, β = −0.184, p = 0.066) were observed to be
inversely associated with age (Supplementary Table S1).
Further, myristic acid (C14:0; p < 0.01), arachidic acid (C20:0; p < 0.05) and DHA (p < 0.05) were observed
to be significantly lower in males (n = 32) compared to females (n = 68), while DPA (C22:5n-3; p < 0.01) was
higher in males compared to females with and without adjusting for appropriate covariates. Furthermore, after
adjusting for covariates, palmitoleic acid (C16:1; p < 0.05) was significantly higher in females compared to males
(Supplementary Table S2).

Erythrocyte fatty acids in APOEε4 carriers and memory complainers. On comparing erythrocyte

FA measured between APOEε4 non-carriers (n = 79) and carriers (n = 21), linoleic acid (C18:2n-6; p < 0.01) and
eicosadienoic acid (C20:2n-6; p < 0.05) were observed to be higher in the non-carriers with and without adjusting
for appropriate covariates. Additionally, dihomo-γ-linolenic acid also appeared to be higher in the non-carriers
after adjusting for appropriate covariates (Supplementary Table S3).
Further, categorising participants into subjective memory complainers (n = 76) and non-complainers
(n = 24), myristic acid was observed to be significantly higher (p = 0.006) in memory complainers compared to
non-complainers, with and without adjusting for covariates age, gender, APOEε4, years of education and NAL
(Supplementary Table S4).

Erythrocyte fatty acids and neocortical beta-amyloid load.

When erythrocyte FA measured in the
current study were compared between low and high NAL, no significant differences were observed in saturated
fatty acids (SFA) and mono unsaturated fatty acids (MUFA) between the two groups, with and without adjusting
for covariates. Within the n-6 PUFA measured, linoleic acid (C18:2n-6; p < 0.05) was significantly lower and AA
(p < 0.05) significantly elevated in high NAL compared to low NAL; however, after adjusting for covariates, only
AA remained significant (p < 0.05). Among the n-3 PUFA measured, linolenic acid (C18:3n-3) was significantly
lower in high NAL (p < 0.05), however after adjusting for covariates the significance in linolenic acid disappeared
while docosapentaenoic acid (DPA, C22:5n-3, p < 0.05) was observed to be significantly lower in high NAL
(Fig. 1). Additionally, a trend of lower EPA concentrations (p = 0.063) and higher stearic acid levels (p = 0.062)
was observed in high NAL compared to low NAL (Table 2).
On investigating associations between NAL and erythrocyte fatty acids measured, a positive trend between
AA concentrations and NAL (β = 0.197, p = 0.050) was observed, while an inverse trend was seen for linoleic acid
(β = −0.172, p = 0.088).

Erythrocyte fatty acids and hippocampal volume. Further an inverse though non-significant association was observed between oleic acid and the left hippocampal volume (β = −0.184, p = 0.073), while DHA
(β = 0.170, p = 0.098) was seen to have a positive though non-significant association with the left hippocampal
volume. Interestingly, within the subjective memory complainer group, these associations between hippocampal
volume and oleic acid (β = −0.264, p = 0.023), and DHA (β = 0.229, p = 0.050) became stronger.
Dietary intake of arachidonic acid and docosapentaenoic acid. Further, to explore whether dietary
FA intake directly attributed to the alterations we observed in erythrocyte fatty acid concentrations, we assessed
the dietary intake of fatty acids that were observed to be significantly different in erythrocytes of participants
with high NAL against those with low NAL (primarily AA, DPA) and between APOEε4 carriers and non-carriers
(linoleic acid, eicosadienoic acid, dihomo-γ-linolenic acid), employing data from the CCVFFQ. No significant
difference was observed in the dietary intake of AA and DPA between high NAL and low NAL with and without
adjusting for covariates age, BMI, years of education and gender (Supplementary Table S5). Further, while lower
Scientific Reports | 7: 676 | DOI:10.1038/s41598-017-00751-2
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Low NAL
(mean ± SD)

High NAL
(mean ± SD)

p

pa

pb

C14:0 (Myristic acid)

0.40 ± 0.07

0.38 ± 0.06

0.184

0.335

0.364

C16:0 (Palmitic acid)

21.94 ± 1.40

21.67 ± 0.85

†0.374

†0.576

†0.610

C18:0 (Stearic acid)

15.70 ± 1.03

16.05 ± 0.80

0.088

0.062

0.080

C20:0 (Arachidic acid)

0.40 ± 0.07

0.42 ± 0.06

0.196

0.128

0.157

C24:0 (Lignoceric acid)

5.03 ± 2.29

4.77 ± 0.84

0.520

0.217

0.236

Total SFA

43.49 ± 0.87

43.31 ± 1.21

0.392

0.157

0.157

C14:1 (Myristoleic acid)

0.01 ± 0.00

0.01 ± 0.01

0.171

0.306

0.313

C16:1 (Palmitoleic acid)

0.34 ± 0.13

0.30 ± 0.08

†0.345

†0.265

†0.239

C18:1n-9 (Oleic acid)

8.74 ± 0.71

8.77 ± 0.64

0.824

0.946

0.887

C18:1n-7 (Vaccenic acid)

1.91 ± 0.43

2.02 ± 0.61

†0.385

†0.865

†0.787

C20:1n-9 (Eicosenoic acid)

0.25 ± 0.05

0.26 ± 0.07

†0.578

†0.231

†0.246

C24:1 (Nervonic acid)

4.92 ± 0.92

5.06 ± 0.89

0.478

0.841

0.831

Total MUFA

16.19 ± 1.25

16.45 ± 1.38

0.334

0.939

0.921

SFA

MUFA

n-6 PUFA
C18:2n-6 (Linoleic acid)

8.82 ± 1.41

8.23 ± 1.48

0.052

0.878

0.924

C18:3n-6 (γ-Linolenic acid) 0.77 ± 0.73

1.08 ± 1.64

†0.928

†0.244

†0.281

C20:2n-6 (Eicosadienoic
acid)

0.14 ± 0.04

0.13 ± 0.04

0.300

0.717

0.668

C20:3n-6 (Dihomo-γlinolenic acid)

1.60 ± 0.46

1.66 ± 0.41

0.586

0.237

0.301

C20:4n-6 (Arachidonic
acid)

15.70 ± 2.12

16.72 ± 1.91

0.020

0.035

0.043

Total omega-6

27.07 ± 2.62

27.84 ± 2.29

0.145

0.023

0.027

n-3 PUFA
0.16 ± 0.10

0.12 ± 0.07

0.033

0.076

0.084

C20:5n-3 (Eicosapentaenoic
1.72 ± 0.96
acid)

1.42 ± 0.69

0.106

0.063

0.068

C22:5n-3
(Docosapentaenoic acid)

3.33 ± 0.64

3.15 ± 0.50

0.143

0.027

0.025

C22:6n-3
(Docosahexaenoic acid)

8.01 ± 1.59

7.68 ± 1.40

0.308

0.458

0.512

Total omega-3

13.24 ± 2.72

12.38 ± 2.20

0.111

0.100

0.116

Omega-3 Index

9.73 ± 2.32

9.10 ± 1.96

0.176

0.337

0.233

C18:3n-3 (Linolenic acid)

Table 2. Erythrocyte fatty acid concentrations in low and high NAL. Using linear models, fatty acid
concentrations were compared between study participants with low (N = 65) and high (N = 35) neocortical
amyloid load (NAL) represented by the standard uptake value ratio (SUVR) of the ligand 18F-Florbetaben in
the neocortical region normalised with that in the cerebellum. Low NAL was defined as SUVR < 1.35 while
high NAL was defined as SUVR ≥ 1.35. pa indicates p values adjusted for age, gender, years of education and
APOE ε4 status; pb indicates p values adjusted age, gender, years of education, APOE ε4 status, body mass index,
fatty acid supplement intake (cod liver oil, flaxseed oil), hormone replacement therapy. ‘†’ indicates p-values
obtained from variables transformed to the logarithmic scale for analyses. SFA: saturated fatty acids; MUFA:
monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; omega-3 index: sum of eicosapentaenoic acid
and docosahexaenoic acid, expressed as a percentage of total erythrocyte fatty acid measured.

dietary intake of eicosadienoic acid and dihomo-γ-linolenic acid were noted based on data from the CCVFFQ in
APOEε4 carriers compared to the non-carriers with and without adjusting for covariates age, BMI, years of education and gender, no significant difference in linoleic acid dietary intake was observed between APOEε4 carriers
and non-carriers (Supplementary Table S5).

Ratio of AA:DPA as a biomarker for predicting high neocortical beta-amyloid load.

Finally,
given the observations of higher AA and lower DPA concentrations in high NAL compared to low NAL, we
also evaluated the ratio of AA:DPA as a potential biomarker, by generating a ‘base’ model comprising age, gender, APOEε4 allele status and education, and compared it with ‘base + AA:DPA’ model, wherein the ratio of
AA:DPA was added to the ‘base’ model. After adjusting for age, gender, APOEε4 allele status and education, the
ratio of AA:DPA was significantly associated with low and high NAL (p = 0.02). The receiver operating characteristic (ROC) curves for the above mentioned models have been presented in Fig. 2, such that the AUC of the
‘base + AA:DPA’ model (AUC = 0.836, 80% sensitivity, 73.8% specificity) was observed to outperform the ‘base’
model (AUC = 0.794, 80% sensitivity, 52.3% specificity).
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Figure 2. Receiver operating characteristic curves for the prediction of high neocortical amyloid load. Receiver
operating characteristic curves of logistic regression modelling shows that the specificity of the ‘base’ model
comprising major risk factors age and APOE ε4 allele status, and gender and education (a) was enhanced by
adding the ratio of AA:DPA i.e. ‘base + AA:DPA’ model (b) at 80% sensitivity. AUC: area under the curve; AA:
arachidonic acid, DPA: Docosapentaenoic acid n-3.

Discussion

The current study reports erythrocyte fatty acid alterations, primarily in, AA and DPA, in elderly individuals with
high NAL against those with low NAL, prior to cognitive impairment and significant differences in hippocampal
atrophy (Table 1).
Elevated levels of erythrocyte AA were observed in high NAL, a feature of preclinical AD, compared to low
NAL. Interestingly, several studies provide evidence to support the contributory role of increased AA to AD
pathogenesis12–14, 17–19. AA and its pro-inflammatory eicosanoid metabolites such as prostaglandins, thromboxanes, and leukotrienes have been reported to promote beta-amyloid secretion13 and therefore not surprisingly AA
metabolism is increased in AD brains12, 14. Furthermore, the depletion of an enzyme responsible for the release of
AA (cytosolic phospholipase A2), has been reported to be protective against deficits in memory and learning in a
transgenic AD mouse model17. AA has been shown to trigger apoptotic pathways in neurons20 and in vitro studies
further suggest that AA promotes tau polymerization18, 19. The above studies consistently demonstrate that AA is
positively associated with AD neuropathology and our findings, further show that an elevation in AA in the blood
at a preclinical stage reflects preclinical-AD related pathogenic changes in the brain.
On the other hand, a decline in erythrocyte DPA (n-3) levels, an intermediate between EPA and DHA, was
observed in high NAL participants compared to low NAL. Given that AA and DPA (n-3) compete for the elongase
enzyme21, it may be posited that elevated AA levels contribute to the declining levels of DPA (n-3) in high NAL.
Interestingly, decreased erythrocyte DPA (n-3) concentrations have been reported in another neurological condition; patients with schizophrenia were observed to have 22% lower erythrocyte DPA (n-3) concentrations compared
to healthy controls22. Conversely, DPA (n-3) supplementation has been observed to have neuroprotective and restorative effects on neuronal function in aged rats which acts through its ability to decrease age related oxidative stress
and microglial activation23, therefore highlighting the anti-oxidative and anti-inflammatory properties of DPA.
DPA (n-3) levels were observed to be significantly lower in females compared to males. We therefore investigated DPA (n-3) levels after categorising participants based on gender and while we continued to find a significant
decline in DPA (n-3) concentrations in high NAL males compared to low NAL males (p < 0.05) with and without
adjusting for covariates, this significance disappeared in females; however, this could be attributed to the modest
sample size available for the observed effect size.
However, in contrast to the significant associations often reported between lower blood DHA (and EPA) concentrations and increased risk to AD in participants with early symptomatic24 or clinical dementia6, 10, 11, significant
alterations in erythrocyte DHA levels were not apparent between high and low NAL participants within the current
study wherein all participants were cognitively normal. Given that previous findings suggest decreased blood DHA
and EPA concentrations are linked with cognitive decline or impairment6, 25, may explain the absence of significantly
declined erythrocyte DHA and EPA observations in high NAL compared to low NAL within the present study
which only comprised participants who were within the cognitively normal range; however, this observation may
also be attributed to the modest sample size employed within the study. Investigating whether participants falling
within the lowest quartile of DHA at baseline (time point used in current study), become symptomatic at their one
year follow-up visit, will provide further insight to our current report. However, the current findings indicate that
alterations in AA and DPA manifest in the asymptomatic stage of the disease, and are not a direct result of dietary
intake, and therefore may shed light on early disease mechanisms that may serve as beneficial therapeutic targets.
Additionally, an inverse association between oleic acid and hippocampal volume was observed; given that
hippocampal atrophy is a pathological hallmark of AD, and that elevated oleic acid concentrations feature in the
more advanced stages of AD pathogenesis26 our findings in subjective memory complainers indicate that oleic
acid may be an early marker for hippocampal atrophy.
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DHA has also been shown to be associated with hippocampal volume in early symptomatic dementia24 and
clinical AD wherein participants with erythrocyte DHA levels in the first quartile, had lower total brain volumes
compared to the upper 3 quartiles27. Similar to findings in our study, a trend of association between DHA and hippocampal volume has been highlighted previously by Pottala et al. in an elderly cohort that was free of dementia28.
Furthermore, on categorizing participants into quartiles based on their erythrocyte DHA levels as employed by
Tan et al., we also observed significantly higher hippocampal volume in participants with erythrocyte DHA levels
in quartile 3 (mean ± SD: 0.20 ± 0.02) compared to quartile 1 (mean ± SD: 0.18 ± 0.01, p = 0.002) and a trend in
quartiles 2 (mean ± SD: 0.19 ± 0.01, p = 0.068) and 4 (mean ± SD: 0.19 ± 0.01, p = 0.058) compared to quartile 1.
In addition, since the ε4 allele of APOE is a well-established risk factor for AD, we also investigated FA differences between non-carriers and carriers of the ε4 allele. Interestingly, significantly lower n-3 PUFA linolenic
acid, and n-6 PUFA, linoleic acid and eicosadienoic acid, were observed in the APOEε4 carriers compared to
the non-carriers. These differences in linoleic acid and eicosadienoic acid remained significant following adjustment for covariates NAL, age, gender, BMI, education, supplement intake and hormone replacement therapy.
Given that the dietary intake of linoleic acid from the CCVFFQ data did not indicate differential dietary intake
between the two groups, it may be posited that an altered metabolism of linoleic acid occurs in APOEε4 carriers29. Additionally, lower linoleic acid concentrations in APOEε4 carriers along with the inverse trend observed
between linoleic acid and NAL, may suggest that decreased linoleic acid may be indicative of an increased risk to
AD; this decreased level of linoleic acid could be a result of increased metabolism of linoleic acid to arachidonic
acid and its metabolites. Our findings in APOEε4 carriers together with several other studies29–33, indicate the
presence of a differential responsiveness to PUFA metabolism.
The erythrocyte FA alterations observed between males and females, and between memory complainers and non-complainers, did not appear to be traceable to their dietary intake as assessed from the CCVFFQ
(Supplementary Table S5). However, the authors acknowledge that data from food frequency questionnaires do
not necessarily reflect an accurate evaluation of the dietary intake of FA but rather serve as a suitable reflection of
exposure to certain food and nutrient types over a period of time, compared to the erythrocyte FA composition
that reflects fatty acid intake or metabolism of approximately 120 days.
To conclude, while it is acknowledged that the current study employs a modest sample size and that further
longitudinal studies with larger sample sizes are required to validate the current novel observations, findings
from the present study may imply that elevated AA and decreased DPA erythrocyte concentrations are an early
event in the AD pathogenesis trajectory. Further, several studies have presented fatty acid alterations associated
with cognitive decline and clinical AD, however the current study, using PET beta-amyloid imaging, is to our
knowledge, the first to report fatty acid alterations associated with the preclinical phase of AD prior to cognitive
impairment and disease related neuronal atrophy. In addition to highlighting the need for a re-evaluation of AA
supplementation as an early therapeutic approach for AD34, 35, given the urgent need for early diagnosis and intervention strategies, our findings also provide insight on a potential early diagnostic candidate as well as alternative
preventative targets for AD. Our findings of elevated AA and decreased DPA in subjects with high NAL indicate
that inflammation and oxidative stress are early features of preclinical AD, and highlights the importance of evaluating anti-inflammatory and anti-oxidative approaches to combat AD pathogenesis at its earliest.

Methods

Participants.

Participants belonged to the McCusker Kerr Anglican Retirement Village Initiative in Ageing
Health (KARVIAH) study cohort, at baseline. Participants were residents of Anglicare (formally known as
Anglican Retirement Villages), aged 65–90 years, living within retirement living accommodations in Sydney,
Australia. Among the 206 volunteers, 143 met the set inclusion and exclusion criteria (refer to supplementary
material) and were deemed eligible for the KARVIAH cohort. One hundred and five participants, out of the 143
volunteers meeting the inclusion and exclusion criteria, at the screening phase for this study, progressed to undertake neuropsychological testing, blood collection and neuroimaging, since the remaining either withdrew from
the study or declined undergoing positron emission tomography.
Following the screening assessment, among the 105 participants, 100 participants were recorded to have a
Mini Mental State Examination (MMSE) score ≥26 at baseline, and were therefore selected for the current study.
Within these 100 participants (of which four reported oral fatty acid supplement intake and two participants were
undergoing hormone replacement therapy), 65 were categorised as low NAL and 35 as high NAL, based on their
neocortical beta-amyloid load assessed via positron emission tomography (PET). Written informed consent was
obtained from all participants. The Bellberry Human Research Ethics Committee Australia provided approval for
the study and all methods were performed in accordance with the relevant guidelines and regulations.

Physical examination and sample processing.

Overnight fasted participants underwent a brief physical examination measuring weight, height, pulse and blood pressure, followed by blood draw. Subsequently,
erythrocytes were isolated from the blood collected and fractionated as previously described36 and were stored at
−80 °C, until used for further analyses. Apolipoprotein E (APOE) genotype was determined from 0.5 ml whole
blood employing standard PCR methodology37.

Erythrocyte fatty acid analysis. Fatty acid derivatisation and gas chromatography. Erythrocyte samples

underwent transesterification prior to gas chromatography38. Briefly, 2 ml of methanol-toluene (4:1, v/v) containing 20 µg/ml of C19:0 as internal standard was added to 200 µl of the thawed sample, followed by the addition of
200 ul acetyl chloride while vortexing, after which the tubes were heated for 1 hour at 100 °C. The tubes were then
cooled in water for 5 min following which 5 ml of 6% K2CO3 was added to the tubes prior to centrifugation at
3000 g for 5 min at 4 °C. The upper toluene phase was collected and stored in a gas chromatography (GC) vial at
−20 °C until GC analysis was performed.
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Fatty acid methyl esters were analysed by gas chromatography (Shimadzu GC-2010 Plus system) using a
30 m × 0.25 mm ID Restek Famewax (Shimadzu Scientific) fused silica capillary column. Ultra-pure hydrogen was
used as a carrier and the oven temperature was programmed from 130 °C to 225 °C at a rate of 6 °C per min. Injector
and detector temperatures were set at 220 °C and 230 °C, respectively. A split ratio of 1:30 and an injection volume of 1 µl
were used. Internal standard methylnonadecanoate (19:0; cat. no. N-5377, Sigma-Aldrich) and a fatty acid mixture (cat.
no. 18919-1AMP SUPELCO, Sigma-Aldrich) were used to compare analysed samples to identify peaks according to
retention time. Calibration curves for each fatty acid were built using a range of concentrations of a mixture of authentic
fatty acid standards. Chromatography data were recorded and integrated using LabSolutions software (Version 5.81
SP1). Individual fatty acid concentrations were reported as a percentage of total erythrocyte fatty acids measured.

Dietary fatty acid intake.

The dietary intake of specific erythrocyte FA observed to be altered between
high and low NAL, and APOEε4 carriers and non-carriers, were investigated to establish whether diet attributed
to the observations made, employing data from the Cancer Council of Victoria Food Frequency Questionnaire
(CCVFFQ)39. The CCVFFQ is a paper-based semi-quantitative seventy-four item questionnaire. The CCVFFQ
was optically scanned to obtain nutrient intakes in gram/day. Participants filled out the CCVFFQ when they
attended the research centre for their baseline assessment.

Neuropsychological tests.

Study participants underwent a comprehensive battery of neuropsychological
tests, measuring episodic memory, executive function, attention, visuospatial abilities, language, processing speed
and working memory, however, for the current study only MMSE (range 0–30, indicating severe impairment to
no impairment) scores40 were employed to confirm no cognitive impairment, and the Memory Assessment Clinic
- Questionnaire (MAC-Q) scores41 were considered to differentiate between subjective memory complainers
(range 25–35) from non-complainers (range ≤24).

Neuroimaging.

All participants within the current study underwent PET imaging using ligand
F-Florbetaben (FBB) and magnetic resonance imaging (MRI) within three months of blood collection, at the
Macquarie Medical Imaging located within Macquarie University Hospital, Sydney, Australia. Participants were
administered an intravenous bolus of FBB slowly over 30 s, while in a rested position. Images were acquired over a
20 min scan beginning 50 min post injection. NAL was calculated as the mean standard uptake value ratio (SUVR)
of the frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate42, 43.
An SUVR cut-off value of 1.35 was utilised to categorise participants into high and low NAL.
In addition, participants underwent a sagittal 3D T1 spoiled gradient recalled acquisition in steady state and
3D T2 fluid-attenuated inversion recovery with axial dual echo Turbo spin echo PD/T2 weighted sequences and
axial T2 star gradient sequence scans, performed on a General Electric 3 Tesla scanner (GE, Model 750 W), utilising a 24 channel head coil. Hippocampal volume was calculated from the images acquired and was normalized by
dividing with the total intracranial volume consisting of the sum of the cerebrospinal fluid, gray matter and white
matter volumes. Due to MRI exclusion criteria and related health conditions, 4 of the 100 were unable to undergo
the MRI imaging component of the study.
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Statistical Analyses.

Descriptive statistics were calculated for low and high NAL groups. Chi-square tests
were employed to compare gender and APOEε4 carrier status between low and high NAL groups. Linear models were utilised to compare continuous parameters between groups of interest, with and without adjusting for
covariates age, gender, APOEε4, education, body mass index, supplement intake and hormone replacement therapy, and to investigate associations between fatty acid measures and age and, neuroimaging data. All continuous
parameters were checked for normality, and those that deviated were transformed appropriately prior to conducting analyses. The receiver operator characteristic (ROC) curves and the area under the curve (AUC) were derived
from the predictive probabilities of the logistic regression models. No correction for multiple comparisons was
made, due to the exploratory nature of the current study. All analyses were carried out using IBM SPSS Version
20, except for the ROC curves, which were generated using package, Deducer on R (version 3.2.5).
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